Recurrence of borderline ovarian tumors: clinical and pathological risk factors

Objective: The objective of this study was to determine the impact of several clinic pathologic factors on the rate of recurrence of borderline ovarian tumors (BOT). Method: Patients, who were diagnosed in our clinic between October 1996 and April 2016 with a final diagnosis of BOT, were retrospectively investigated. Only patients with a primary diagnosis of BOT were included. A total of 147 patients were diagnosed with BOT and underwent surgical treatment. The pathological reports, medical records and operation notes of the included patients were obtained from the gynecological oncology electronic database system. Results: While 51.7% of all our patients had BOTs of serous histology, 34.6% had mucinous BOTs and 13.6% had seromucinous BOTs, and their bilaterality was 11.8%, 2% and 5%, respectively. After treatment, the clinical conditions of 96 patients could be followed and recurrence was observed in six (6.3%) of them. The median follow-up time was 66 months (range: 12–266 months). The median time to recurrence was 46 months (range: 14–100 months). For non-recurrence and recurrence cases, the median age was 42.0 years (range: 17–86) years and 29.0 years (range: 18–32 years), respectively a statistically significant difference (p = 0.005). Thirteen percent of the patients who underwent conservative surgery had recurrence, whereas no recurrence was observed in patients without conservative surgery (p = 0.009). While no recurrence was observed in patients who were surgically staged as stage 1, recurrences developed in cases with stage 2 and 3 disease (p = 0.040). In this cohort histologic type, surgical staging, presence of implants, size of the tumor, presence of micropapillary variants, and lymphadenectomy were not associated with recurrence. Conclusion: We found the recurrence of BOT is associated with younger age at diagnosis and conservative surgery. Although we found no statistically significant association of BOT recurrences with surgical staging, among those who were surgically stage recurrences only occured in patients with stage 2 or 3 disease.

Borderline ovarian tumors; Cancer; Neoplasm; Recurrence; Risk factors; Surgery

[1] Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. International Journal of Cancer. 2008; 123: 1897–1901.

[2] Taylor HC. Malignant and semimalignant tumors of the ovary. Surgery, Gynecology and Obstetrics. 1929; 48: 204–230.

[3] Akeson M, Zetterqvist B, Dahllöf K, Jakobsen A, Brännström M, Horvath G. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. International Journal of Gynecological Cancer. 2008; 18: 453–459.

[4] Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. International Journal of Gynecology & Obstetrics. 2000; 70: 209–262.

[5] Lazarou A, Fotopoulou C, Coumbos A, Sehouli J, Vasiljeva J, Braicu I, et al. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors. Anticancer Research. 2014; 34: 6725–6730.

[6] Burks RT, Sherman ME, Kurman RJ. Micropapillary serous car- cinoma of the ovary. a distinctive low-grade carcinoma related to serous borderline tumors. The American Journal of Surgical Pathology. 1996; 20: 1319–1330.

[7] Eichhorn JH, Bell DA, Young RH, Scully RE. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. The American Journal of Surgical Pathology. 1999; 23: 397– 409.

[8] Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer. 1988; 62: 2212–2222.

[9] McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. The American Journal of Surgical Pathology. 2006; 30: 614–624.

[10] Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynaecology and Obstetrics. 2014; 124: 1–5.

[11] Park J, Kim D, Kim J, Kim Y, Kim Y, Nam J. Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecologic Oncology. 2009; 113: 75–82.

[12] Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treat- ment, and follow-up of borderline ovarian tumors. The Oncologist. 2012; 17: 1515–1533.

[13] Sobiczewski P, Kupryjanczyk J, Michalski W, Śpiewankiewicz B. The evaluation of risk factors associated with relapse and recurrence of borderline ovarian tumors with long-term follow-up. International Journal of Gynecological Cancer. 2016; 26: 1053– 1061.

[14] Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovar- ian borderline tumours: a meta-analysis with emphasis on recurrence risk. European Journal of Cancer. 2015; 51: 620–631.

[15] Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, et al. Risk factors for recurrence of ovarian borderline tumors. Gynecologic Oncology. 2011; 120: 480–484.

[16] Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, et al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Annals of Oncology. 2014; 25: 1320–1327.

[17] Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. Journal of Clinical Oncology. 2001; 19: 2658–2664.

[18] Obermair A, Tang A, Kondalsamy–Chennakesavan S, Ngan H, Zusterzeel P, Quinn M, et al. Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. International Journal of Gynecological Cancer. 2013; 23: 264–267.

[19] Plett H, Harter P, Ataseven B, Heitz F, Prader S, Schneider S, et al. Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecologic Oncology. 2020; 157: 411–417.

[20] Huang Y, Zhang W, Wang Y. The feasibility of fertility-sparing surgery in treating advanced-stage borderline ovarian tumors: a meta-analysis. Taiwanese Journal of Obstetrics & Gynecology. 2016; 55: 319–325.

[21] Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstetrics and Gynecology. 1988; 72: 775–781.

[22] Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertility and Sterility. 2001; 75: 92–96.

[23] Delle Marchette M, Ceppi L, Andreano A, Bonazzi CM, Buda A, Grassi T, et al. Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery. European Journal of Cancer. 2019; 111: 61–68.

[24] Lesieur B, Kane A, Duvillard P, Gouy S, Pautier P, Lhommé C, et al. Prognostic value of lymph node involvement in ovarian serous borderline tumors. American Journal of Obstetrics and Gynecology. 2011; 204: 438.e1–438.e7.

[25] Camatte S, Rouzier R, Boccara-Dekeyser J, Pautier P, Pomel C, Lhomme C, et al. Prognosis and fertility after conservative treatment for ovarian tumors of limited malignity: review of 68 cases. Gynecologie, Obstetrique & Fertilite. 2002; 30: 583–591.

[26] Guvenal T, Dursun P, Hasdemir PS, Hanhan M, Guven S, Yetimalar H, et al. Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study. Gynecologic Oncology. 2013; 131: 546–550.

[27] Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Human Pathology. 2000; 31: 539–557.

[28] Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, et al. Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecologic Oncology. 2017; 144: 496–502.

[29] Ureyen I, Karalok A, Tasci T, Turkmen O, Boran N, Tulunay G, et al. The factors predicting recurrence in patients with serous borderline ovarian tumor. International Journal of Gynecological Cancer. 2016; 26: 66–72.

[30] Kristensen GS, Schledermann D, Mogensen O, Jochumsen KM. The value of random biopsies, omentectomy, and hysterectomy in operations for borderline ovarian tumors. International Journal of Gynecologic Cancer. 2014; 24: 874–879.

[31] Wu TI, Lee CL, Wu MY, Hsueh S, Huang KG, Yeh CJ, et al. Prognostic factors predicting recurrence in borderline ovarian tumors. Gynecologic Oncology. 2009; 114: 237–241.

[32] Tang A, Kondalsamy-Chennakesavan S, Ngan H, Zusterzeel P, Quinn M, Carter J, et al. Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801) Gynecologic Oncology. 2012; 126: 36–40.

[33] du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. European Journal of Cancer. 2013; 49: 1905– 1914.

[34] Park J, Kim D, Kim J, Kim Y, Kim K, Kim Y, et al. Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecologic Oncology. 2011; 123: 511–516.

[35] Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. The American Journal of Surgical Pathology. 2002; 26: 1111–1128.

[36] Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Human Pathology. 2004; 35: 934–948.

[37] Lu Z, Chen J. Introduction of WHO classification of tumours of female reproductive organs, fourth edition. Zhonghua Bing Li Xue Za Zhi. 2014; 43: 649–650. (In Chinese)